<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 3; Issue 1, (Jan-Jun,2022)</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>Cancer Case Reports</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Cancer Case Reports</ArticleType>
      <ArticleTitle>Genetic Analysis of Medullary Thyroid Cancer in Algiers, Algeria</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>8</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Ammar</FirstName>
          <LastName>CHIKOUCHE</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Nadia OULD</FirstName>
          <LastName>BESSI</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Nawal</FirstName>
          <LastName>HABAK</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Mebarek</FirstName>
          <LastName>BOUDISSA</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Saïda</FirstName>
          <LastName>FEDALA</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Malika</FirstName>
          <LastName>REZOUG</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Lakhdar</FirstName>
          <LastName>GRIENE</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Medullary thyroid cancer or MTC occurs sporadically (75% of cases) and familial form (25% of cases) which, in the latter situation, is part of Multiple Endocrine Neoplasia type 2 (MEN2). The MEN2 are subdivided into MEN2A, MEN2B and FMTC or isolated family MTC. MEN2 are rare inherited conditions, transmitted in the autosomal dominant mode, linked to mutations in the RET gene. We report the results of the genotypic study carried out at the CPMC in Algiers, in 209 index cases with medullary thyroid cancer or MEN2. 24.40 % of index cases are classified as MEN2, 47 of which carry germline mutations in the RET gene. Mutations in the seven (07) different exons of the RET gene have been found.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Multiple Endocrine Neoplasia Type 2,Medullary Thyroid Carcinoma,FMTC,Protooncogene RET,Mutation</Keywords>
      <URLs>
        <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=15157&amp;title=Genetic Analysis of Medullary Thyroid Cancer in Algiers, Algeria</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Airaksinen MS and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3: 383-394.&#13;
&#13;
Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005; 16: 441-467.&#13;
&#13;
Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA Jr. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986; 73: 278-281.&#13;
&#13;
Franc B and Modigliani E. Le carcinome mand;eacute;dullaire de la thyroand;iuml;de: and;eacute;volution des concepts. Arch Anat Cytol Pathol 1998; 46: 100-111.&#13;
&#13;
Gorlin RJ, Sedano HO, Vickers RA, Cervenka J. Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid-a syndrome. Cancer 1968; 22: 293-299.&#13;
&#13;
Groupe d’Etude des tumeurs endocrines GTE (2006) Cancer Mand;eacute;dullaire de la Thyroand;iuml;de et Nand;eacute;oplasies Endocriniennes Multiples de type 2; Recommandations pour la Prise en Charge Diagnostique et Thand;eacute;rapeutique; Edition Janvier 2006.&#13;
&#13;
Hansford JR and Mulligan LM. Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis. J Med Genet 2000; 37: 817-827.&#13;
&#13;
Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hand;ouml;ppener JW, van Amstel HK, Romeo G, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-356.&#13;
&#13;
Ishizaka Y, Itoh F, Tahira T, Ikeda I, Sugimura T, Tucker J, Fertitta A, Carrano AV, Nagao M. Human ret proto-oncogene mapped to chromosome 10q11. 2. Oncogene 1989; 4: 1519-1521.&#13;
&#13;
Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hand;uuml;fner M, Niederle B, Brabant G; German Society for Endocrinology (DGE) - Thyroid Section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58.&#13;
&#13;
Kini S, Miller J, Hamburger J, Smith M. Cytopathologic features of medullary carcinoma of the thyroid. Arch Pathol Lab Med 1984; 108: 156.&#13;
&#13;
Kwok JB, Gardner E, Warner JP, Ponder BA, Mulligan LM. Structural analysis of the human ret proto-oncogene using exon trapping. Oncogene 1993; 8: 2575-2582.&#13;
&#13;
Miralliand;eacute; E, Iacobone M, Sebag F, Henry J. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol 2004; 30: 790-795.&#13;
&#13;
Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3and;#39;splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 1995; 11: 2039-2045.&#13;
&#13;
Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E, Conte-Devolx B. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997; 82: 338-341.&#13;
&#13;
Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (New York, NY) 1995; 267: 381-383.&#13;
&#13;
Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961;31(1):163-6.&#13;
&#13;
Takahashi M and Cooper GM. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987; 7: 1378-1385.&#13;
&#13;
Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42: 581-588.&#13;
&#13;
van Heyningen V. Genetics: One gene--four syndromes. Nature 1994; 367: 319-320.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>